Theseus Pharmaceuticals, Inc.
(NASDAQ : THRX)

( )
THRX After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen, Inc. -0.40%282.621.5%$846.35m
MRNAModerna, Inc. -0.58%175.380.0%$764.29m
GILDGilead Sciences, Inc. -1.22%85.211.0%$712.21m
REGNRegeneron Pharmaceuticals, Inc. 0.71%741.482.6%$477.59m
VRTXVertex Pharmaceuticals, Inc. 0.74%315.301.9%$412.70m
BIIBBiogen, Inc. -4.34%291.901.8%$344.20m
ILMNIllumina, Inc. -0.95%216.913.2%$252.36m
SNSSSunesis Pharmaceuticals, Inc. -9.35%2.520.7%$176.16m
BNTXBioNTech SE 4.29%161.490.0%$168.04m
BMRNBioMarin Pharmaceutical, Inc. 1.80%98.664.2%$153.96m
AXSMAxsome Therapeutics, Inc. 31.54%74.741.6%$145.83m
MRTXMirati Therapeutics, Inc. -2.99%95.671.6%$134.05m
TECHBio-Techne Corp. -2.53%330.404.5%$124.21m
NVAXNovavax, Inc. 0.61%16.6475.3%$71.50m
HALOHalozyme Therapeutics, Inc. 3.29%56.4718.4%$70.68m

Company Profile

Theseus Pharmaceuticals, Inc. engages in the development of pan-variant kinase inhibitors. It focuses on the discovery, development and commercialization of transformative targeted therapies. The company was founded by William C. Shakespeare, David C. Dalgarno, Iain D. Dukes, Wei Sheng Huang and Victor M. Rivera on December 29, 2017 and is headquartered in Cambridge, MA.